Interferon Gamma Release Assay Results and Testing Trends Among Patients Younger Than 2 Years Old at Two US Health Centers. [PDF]
Tabatneck ME +8 more
europepmc +1 more source
A novel neutrophil‐hitchhiking, rocket‐inspired nanoplatform is developed to cross the blood‐brain barrier for sequential, spatiotemporal drug delivery. By responsive surface transformation in the ischemic penumbra, it precisely targets mitochondria to suppress Drp1‐mediated fission.
He Bai +17 more
wiley +1 more source
Resolution pharmacology is an emerging strategy to tackle inflammatory pathologies. Bioinspired meroterpenoids induce a lipid mediator class switch toward inflammation resolution in vitro and in vivo by targeting key nodes in lipid mediator biosynthesis and neutral lipid dynamics.
Lorenz Waltl +20 more
wiley +1 more source
The Interferon-Gamma Release Assay versus the Tuberculin Skin Test in the Diagnosis of Mycobacterium tuberculosis Infection in BCG-Vaccinated Children and Adolescents Exposed or Not Exposed to Contagious TB. [PDF]
Druszczynska M +5 more
europepmc +1 more source
BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu +12 more
wiley +1 more source
Utility of Mantoux and Interferon-gamma Release Assays
openaire +1 more source
Evaluation of an interferon-gamma release assay for early detection of lumpy skin disease virus infection and vaccination in cattle. [PDF]
Kresic N +3 more
europepmc +1 more source
Interferon-gamma release assay has poor diagnostic accuracy in differentiating intestinal tuberculosis from Crohn's disease in tuberculosis endemic areas. [PDF]
Sachdeva K +10 more
europepmc +1 more source
Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan +9 more
wiley +1 more source
Antitubercular therapy for uveitis of undetermined cause with positive interferon-gamma release assay: a single-blind, single-centre, phase 2 randomised controlled trial. [PDF]
La Distia Nora R +15 more
europepmc +1 more source

